Atomo Diagnostics (ASX:AT1) has secured a significant new order for its patented Pascal cassette, with strategic partner Lumos Diagnostics (ASX:LDX) placing a US$410,000 (A$630,000) order to support increasing demand for the FebriDx® test in the United States. This is the first Pascal order since Lumos entered a six-year exclusive US distribution agreement with PHASE Scientific,
Read More
Ranked fourth among countries with the highest HIV prevalence in the world, there were about 7.5 million people living with HIV in South Africa in 2021, and the number keeps growing. Subsequently, the HIV test market in South Africa is also growing as HIV testing initiatives have been implemented to increase access to testing and
Read More
Three companies are joining forces to help tackle one of the most serious public health challenges of our time – the HIV/AIDS epidemic. Viatris and Atomo Diagnostics (ASX: AT1) have announced an agreement with Unitaid to increase accessibility of HIV self-testing in low-and middle-income countries (LMICs). The announcement represents significant market expansion, with Unitaid committing
Read More
Medtech company Atomo Diagnostics (ASX: AT1) has been granted regulatory approval in Australia for their patented AtomoRapid HIV (1&2) rapid diagnostic kit which will enable testing for HIV with just one drop of blood. The approval granted by the Therapeutic Goods Association (TAG) enables Atomo to commence distribution of the diagnostic test to medical professionals
Read More
With only one company set to list this month, it appears that the volatility that surrounds the ASX is prompting some companies to delay listing until some degree of normality in financial markets is restored. One company brave enough to face the current environment is Atomo Diagnostics Limited (Proposed ASX: AT1). The Sydney-based medical diagnostics
Read More